Synapse - Works

Results (40)

Combined RAF and MEK inhibition to treat activated non-V600 BRAF-altered advanced cancers

Journal Article

Rustgi, N.; Maria, A.; Toumbacaris, N.; Zhao, H.; Kargus, K.; Bryant, M.; Waksmundzki, A.; Aricescu, I.; Lefkowitz, R. A.; Li, B. T.; more...
The Oncologist (2024)

Fulltext@MSK | Save

Efficacy of BRAF inhibitor plixorafenib (Fore8394) in recurrent, primary central nervous system tumors (PCNST)

Meeting Abstract

de la Fuente, M.; Butowski, N.; Taylor, J.; Yaeger, R.; Tsai, F. Y. C.; Janku, F.; Allen, C.; Ammakkanavar, N.; Michelson, G.; Jiang, P.; more...
Neuro-Oncology (2023)

Fulltext@MSK | Save

Genomic characteristics and clinical outcomes of stereotactic radiosurgery for colorectal cancer brain metastases

Meeting Abstract

Gui, C.; Walch, H.; Mueller, K.; Eichholz, J.; Khatri, I.; Del Balzo, L.; Kemeny, N.; Imber, B.; Schultz, N.; Foote, M.; more...
Neuro-Oncology (2023)

Fulltext@MSK | Save

PD-1 blockade as curative intent therapy in mismatch repair deficient locally advanced rectal cancer

Meeting Abstract

Cercek, A.; Lumish, M.; Sinopoli, J.; Weiss, J.; Shia, J.; Stadler, Z.; Yaeger, R.; Smith, J. J.; Saltz, L.; Widmar, M.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Adagrasib with or without cetuximab in patients with KRASG12C-mutated colorectal cancer (CRC): Analysis of tumor biomarkers and genomic alterations

Meeting Abstract

Pelster, M. S.; Yaeger, R.; Klempner, S. J.; Ou, S. H. I.; Spira, A. I.; Jänne, P. A.; Uboha, N. V.; Gaffar, Y. A.; Newman, G.; Paweletz, C. P.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Phase Ib/II study of the efficacy and safety of binimetinib (MEK162) plus panitumumab for mutant or wild-type RAS metastatic colorectal cancer

Journal Article

Van Cutsem, E.; Yaeger, R.; Delord, J. P.; Tabernero, J.; Siu, L. L.; Ducreux, M.; Siena, S.; Elez, E.; Kasper, S.; Zander, T.; more...
The Oncologist (2023)

Fulltext@MSK | Save

Clinical characteristics, efficacy, and safety in patients receiving second- or third-line encorafenib plus cetuximab (E+C) vs control for metastatic colorectal cancer (mCRC): BEACON CRC post hoc analysis

Meeting Abstract

Tabernero, J.; Van Cutsem, E.; Yoshino, T.; Yaeger, R.; Wasan, H.; Desai, J.; Ciardiello, F.; Alkuzweny, B.; Zhang, X.; Guenzil, C.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort

Meeting Abstract

Kuboki, Y.; Yaeger, R.; Fakih, M.; Strickler, J. H.; Masuishi, T.; Kim, E. J. H.; Bestvina, C. M.; Langer, C. J.; Krauss, J. C.; Puri, S.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC)

Meeting Abstract

Tabernero, J.; Yoshino, T.; Kim, T. W.; Yaeger, R.; Desai, J.; Wasan, H. S.; Van Cutsem, E.; Ciardiello, F.; Maughan, T.; Eng, C.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

KRYSTAL-1: Updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation

Meeting Abstract

Klempner, S. J.; Weiss, J.; Pelster, M.; Spira, A.; Barve, M.; Ou, S. H. I.; Leal, A.; Bekaii-Saab, T.; Christensen, J. G.; Kheoh, T.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save